Antibody‐Dependent Cellular Cytotoxicity of iPS Cell‐Derived Natural Killer T Cells by Anti‐ GD2 mAb for Neuroblastoma
Cancer Science · 2025
DOI: 10.1111/cas.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Katsuhiro Nishimura und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Neuroblastoma, Antibody-Dependent Cell Cytotoxicity, Gangliosides, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kashiwado Memorial Foundation for Medical Research, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
While antibody‐dependent cellular cytotoxicity (ADCC) by anti‐disialoganglioside GD2 monoclonal antibody (mAb) has succeeded in increasing the survival rate of high‐risk patients with neuroblastoma, approximately 40%–50% of patients die from the disease. Recently, we developed induced pluripotent stem cell‐derived natural killer T (iPS‐NKT) cells, which exhibit NK‐like cytotoxicity. However, whether iPS‐NKT cells can induce ADCC function is unclear. Here, we investigated the ADCC of iPS‐NKT cells and the efficacy of the combination treatment of anti‐GD2 mAb and iPS‐NKT cells against neuroblastoma. Anti‐GD2 mAb enhanced the cytotoxicity and secretion of cytokines and cytotoxic granules of iPS‐NKT cells, which expressed CD16 to GD2‐expressing neuroblastoma cell lines. We also examined which Fcγ receptors contribute to ADCC of iPS‐NKT cells. CD16 stimulation against iPS‐NKT cells caused cytotoxicity and secretion of interferon‐gamma, tumor necrosis factor, and granzyme B. In contrast, CD32 and CD64 stimulation did not. In vivo, the intratumor administration of anti‐GD2 mAb and iPS‐NKT cells significantly inhibited tumor growth compared with the other treatment groups: no treatment, anti‐GD2 mAb alone, and iPS‐NKT cells alone. In conclusion, iPS‐NKT cells exhibit CD16‐mediated ADCC, and the addition of iPS‐NKT cells to anti‐GD2 mAb therapy may be a potential approach for immunotherapy against neuroblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Pediatric Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
- Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
ORCID-Profile: Takahiro Aoki, Shinichiro Motohashi
Förderung
- Kashiwado Memorial Foundation for Medical Research
- Japan Society for the Promotion of Science
Zitieren
APA
Nishimura, K., Aoki, T., Kobayashi, M., Takami, M., Ozaki, K., Ogawa, K., Hongxuan, W., Shimizu, D., Katsumi, D., Yoshizawa, H., Komatsu, S., Takatani, T., Hirahara, K., Koseki, H., Hishiki, T., & Motohashi, S. (2025). Antibody‐Dependent Cellular Cytotoxicity of iPS Cell‐Derived Natural Killer T Cells by Anti‐ GD2 mAb for Neuroblastoma. Cancer Science. https://doi.org/10.1111/cas.70008
Vancouver
Nishimura K, Aoki T, Kobayashi M, Takami M, Ozaki K, Ogawa K, et al. Antibody‐Dependent Cellular Cytotoxicity of iPS Cell‐Derived Natural Killer T Cells by Anti‐ GD2 mAb for Neuroblastoma. Cancer Science. 2025. doi:10.1111/cas.70008
BibTeX
@article{Nishimura2025,
author = {Nishimura, Katsuhiro and Aoki, Takahiro and Kobayashi, Midori and Takami, Mariko and Ozaki, Ko and Ogawa, Keita and Hongxuan, Wang and Shimizu, Daiki and Katsumi, Daisuke and Yoshizawa, Hiroko and Komatsu, Shugo and Takatani, Tomozumi and Hirahara, Kiyoshi and Koseki, Haruhiko and Hishiki, Tomoro and Motohashi, Shinichiro},
title = {Antibody‐Dependent Cellular Cytotoxicity of iPS Cell‐Derived Natural Killer T Cells by Anti‐ GD2 mAb for Neuroblastoma},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70008}
}
EUVIMED